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Background:  GS-4774  is  a recombinant,  heat-killed,  yeast-based  immunotherapy  engineered  to  express
hepatitis B  virus  (HBV)-speciﬁc  antigens.  GS-4774  is being  developed  as  a therapeutic  vaccine  for  chronic
HBV  infection.  The  aim  of this  study  was  to  assess  the  safety,  tolerability  and  immunogenicity  of  GS-4774
in healthy  subjects.
Design: This was  a randomized,  open-label,  dose-ascending  study.  Subjects  were  allocated  to  one  of  three
dose groups  (n =  20  per  group)  to receive  10, 40  or 80 yeast  units  (YU;  1  YU = 107 yeast)  of  GS-4774  in
two  immunization  regimens  (ﬁve  subcutaneous  injections  at weekly  intervals  with  one  monthly  booster
or three  subcutaneous  injections  at monthly  intervals).  T-cell-mediated  responses  were  determined  by
interferon  (IFN)-  enzyme-linked  immunospot  (ELISpot)  assay  and  lymphocyte-proliferation  assay  (LPA).
Results:  Adverse  events  were  reported  by 39  of 60 (65%)  subjects;  all  were  mild  or moderate  and  none
was  serious.  Adverse  events  occurred  most  frequently  in the  highest  dose  group,  80 YU,  and  the number
of  individual  events  was  higher  after  weekly  immunization  than  monthly.  The  most  common  adverse
events  were  injection-site  reactions.  Most  (88%)  subjects  responded  to GS-4774  by at least  one  of  the T-cell
assays.  Following  immunization  with  GS-4774,  IFN--producing  T-cells  speciﬁc  for HBV  antigens  were
detectable  in  30 (51%)  subjects.  The  ELISpot  response  was  observed  at all doses,  with  the  highest  frequency
of responders  occurring  at the  highest  dose  (10  YU:  45%;  40 YU:  35%;  80  YU:  74%).  Proliferative  responses
to  HBV  recombinant  antigens  were  observed  in  90%  subjects;  responses  were  mainly  independent  of
GS-4774  dose  and  immunization  regimen.
Conclusions:  GS-4774  was  safe and  well-tolerated  in  healthy  subjects  with  injection-site  reactions  being
the  most  frequently  reported  adverse  events.  With  both  weekly  and  monthly  regimens,  GS-4774  pro-
vided  HBV-speciﬁc  immune  responses  at  all  doses  evaluated.  Further  evaluation  of  GS-4774 is  ongoing
in  patients  with  chronic  HBV  infection.
Clinical  trial registry:  Clinicaltrials.gov  (NCT01779505)
© 2014  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
Viral clearance of acute HBV infection depends on a rigorous
D4+ and CD8+ T-cell-mediated response directed against HBV-
peciﬁc antigens that includes production of interferon (IFN)-
1–4]. In patients with chronic HBV infection, T-cell responses and
FN- production are both severely impaired, contributing to the
∗ Corresponding author. Tel.: +1 650 574 3000; fax: +1 650 522 1975.
E-mail address: anuj.gaggar@gilead.com (A. Gaggar).
ttp://dx.doi.org/10.1016/j.vaccine.2014.07.027
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
persistence of their HBV infection [1,3,4]. Currently available drugs
are capable of controlling viremia but rarely eradicate the virus [5].
Therefore, to achieve a cure (deﬁned as hepatitis B surface antigen
[HBsAg] seroconversion), new therapies targeting HBV replication
and the immune system are needed [5].
GS-4774 (formerly GI-13020) is being developed to elicit an
HBV-speciﬁc T-cell immune response in patients with chronic HBV
infection. GS-4774 consists of heat-inactivated yeast cells that
express well-conserved regions of HBV proteins, namely HBsAg,
hepatitis B core antigen (HBcAg) and hepatitis B X protein (HBx)
expressed as a single fusion protein. The recombinant heat-killed
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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hole yeast platform has been previously shown to elicit a sig-
iﬁcant T-cell response upon subcutaneous administration [6].
reclinical experiments in mice showed that GS-4774 elicited T-
ell responses speciﬁc to HBsAg, HBcAg, and HBx and stimulated
BV-speciﬁc CD8+ T-cells [7]. In cells from patients with chronic
BV infection, GS-4774 induced IFN--producing CD4+ and CD8+
 cells that, in some cases, showed marked levels of expression of
he Lamp-1/CD107a marker of cytotoxic function [8]. These exper-
ments suggested that GS-4774 had potential to elicit an antiviral
mmune response. The present work was a ﬁrst-time-in-human
linical trial of GS-4774 in healthy subjects.
. Methods
.1. Subjects
Healthy subjects aged ≥18 years were eligible. Subjects were
ecruited using a database of healthy volunteers elicited using
dvertisements in the community. Before enrolment, subjects had
o demonstrate negative immunoglobulin (Ig) E-mediated hyper-
ensitivity to Saccharomyces cerevisiae.  Detailed exclusion criteria
re provided in Supplementary File 1. All patients were negative
or HBV DNA and anti-HBc antibodies. Four subjects had low-level
ntibodies to HBsAg below the threshold for positivity.
All subjects provided informed consent prior to screening.
ocal Ethics Review Committees approved the study, which was
onducted in accordance with Good Clinical Practice and the Dec-
aration of Helsinki.
.2. Study design
Single-site, randomized, open-label, dose-ascending, multi-arm
tudy conducted in the USA between January and July 2013. Sub-
ects were allocated to one of three dose groups (n = 20 per group) to
eceive 10, 40 or 80 yeast units (YU) (1 YU = 107 yeast cells) of study
reatment. Within each group, subjects were randomized into two
osing cohorts (each n = 10): Cohort A received ﬁve injections of
tudy treatment at weekly intervals plus another dose on day 57;
ohort B received three injections of study treatment at monthly
ntervals; the post-treatment period was deﬁned as the 4-week
eriod following the last dose. Further details of the protocol are
iven in Supplementary File 1.
At the start of the study, the exclusion threshold for anti-
BsAg antibody levels was 8.4 IU/L. However, in February 2013, the
hreshold levels were reduced to <3.5 IU/L to exclude any subjects
ith even low levels of HBV immunity. Four subjects enrolled and
osed who had screening levels ≥3.5 but ≤8.4 IU/L were permitted
o continue the study. These subjects all had values for anti-HBsAg
hat were below the threshold of having a positive anti-HBsAg test
nd were negative for anti-HBcAg and for HBV DNA.
.3. Study treatment
GS-4774 (Supplementary Figure 1; Globeimmune, Louisville,
O, and Integrity Bio, Camarillo, CA) was administered by 25 Gauge
/8′ needle.
.4. Safety and tolerability assessments
Primary endpoints were: frequency of serious adverse events,
iscontinuations from treatment due to adverse events, abnor-
al  common laboratory parameters, dose-limiting toxicities, and
requency and intensity of common adverse events. Safety was
ssessed by physical examination, vital signs measurements, (2014) 4925–4931
electrocardiogram (ECG), clinical laboratory tests and adverse
event and concomitant medications monitoring.
2.5. Immunogenicity assessments
Secondary endpoint was immunogenicity of different dosing
regimens of GS-4774.
2.6. Samples for immune function assays
Blood samples were collected before study treatment adminis-
tration at baseline (day 1 or screening), on days 15, 29, 36, and 57 of
treatment and on day 28 of the post-treatment period. Peripheral
blood mononuclear cells (PBMCs) were isolated by Ficoll density
gradient centrifugation and frozen in liquid nitrogen until analysis.
2.7. Interferon- enzyme-linked immunospot assay
Sterile 96-well plates (PVDF membranes, Millipore, Bedford,
MA)  were coated overnight at 4 ◦C with anti-human IFN-
antibody (Thermo Scientiﬁc, Rockford, IL), then stimulants and
PBMCs were added each in a volume of 100 L. Thawed PBMCs
(4 × 105 cells/well) were stimulated with: assay medium alone
(serum-free medium, CTL-TestTM PLUS medium, Cellular Technol-
ogy Ltd. [CTL], Shaker Heights, OH); HBV recombinant antigens
namely HBsAg (Prospec-Tany Technogene, Ness Ziona, Israel),
HBcAg (Fitzgerald Industries International, Acton, MA), and HBx
(Prospec-Tany) (10 g/mL each); pools of overlapping 15-mer HBV
peptides (overlapping by nine amino acids) spanning the entire
GS–4774 insert sequence (12.5 g/mL each); pools of discrete pep-
tides (8–17 amino acids in length) known to be HBV-speciﬁc T-cell
epitopes (25 g/mL); and single peptides also known to be HBV-
speciﬁc T-cell epitopes (25 g/mL) (Supplementary Tables 1 and 2).
All HBV peptides were based on HBV Genotype D and produced by
Mimotopes (Clayton, Australia) except for single peptides FLLTRILTI
and FLPSDFFPSV (Peptide 2.0, Chantilly, VA).
Positive controls were phytohemagglutinin (PHA;
Sigma–Aldrich, St. Louis, MO;  5 g/mL) and a pool of known CD8+
T-cell epitopes (2 g/mL) from cytomegalovirus, Epstein–Barr
virus, and inﬂuenza virus ([9]; EZBioLab, Carmel, IN). A pool of HIV
peptides (Mimotopes; 25 g/mL) was  used as negative control
(Supplementary Table 3). Cells were incubated with stimulants at
37 ◦C and 5% CO2 for 24 h. Plates were washed and biotinylated
anti-human IFN- antibody (Thermo Scientiﬁc) was  added to each
well. Plates were refrigerated overnight. Thereafter, plates were
washed and streptavidin-HRP (BD Biosciences, San Jose, CA) was
added to each well and incubated for 2 h. Plates were washed
and air-dried, and the substrate 3-amino-9-ethyl carbazole was
added. Numbers of IFN--secreting cells (“spots”) were measured
by anti-IFN- capture antibody and adjusted for background
(medium alone) and baseline response. Spots were counted
by CTL ImmunoSpot® Analyzer (CTL); data were processed by
SpotMap® software. An immune response was pre-speciﬁed by
algorithms that evaluated T-cell IFN- responses in terms of
breadth, duration, and magnitude. In addition, a response to any
pool or antigen was  required to be ≥2-fold over assay background
and display at least a 2-fold increase from baseline (Supplementary
Table 4).
2.8. Lymphocyte proliferation assay
Thawed PBMCs (2 × 105 cells/well) were incubated with HBsAg,
HBcAg, and HBx (1 and 10 g/mL each). Candida albicans extract
(Greer Labs., Lenoir, NC; 20 g/mL), tetanus toxoid (Colorado
Serum Company, Denver, CO; 0.25 limes ﬂocculation units/mL),
and PHA (Roche Diagnostics, Indianapolis, IN, 5 or 12.5 g/mL)
A. Gaggar et al. / Vaccine 32 (2014) 4925–4931 4927
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ere used as positive controls. Assay medium was  used as negative
ontrol. Cells were incubated with test antigens in a humidi-
ed incubator at 37 ◦C and 5% CO2 for 6 days. Proliferation was
easured by uptake of 3H-thymidine (Packard Topcount NXT,
owners Grove, IL), which was added for the ﬁnal 6 h of incu-
ation, using a beta scintillation counter. PHA stimulation was
easured after 3 days. The stimulation index (SI) for each antigen
as calculated as the ratio of the median response in the pres-
nce and absence of antigen. A response was deﬁned as SI ≥2 over
aseline.
.9. Anti-S. cerevisiae antibody detection
Serum was harvested from blood samples collected before
tudy treatment administration on days 1 and 29, and on day 28
f the post-treatment period. Anti-S. cerevisiae antibody (ASCA)
gA and IgG levels were measured by Quanta LiteTM ELISA kits
INOVA Diagnostics, San Diego, CA). Both ASCA IgA and IgG are
nown to bind to a speciﬁc epitope present in the cell wall of S.
erevisiae [10,11]. An ASCA value ≥25 U on treatment after sub-
raction of baseline unit value was considered to be a positive
esponse.
.10. Anti-HBsAg and anti-HBcAg antibody detection
Serum was harvested from blood samples collected before study
reatment administration at screening and on days 1, 15, 29, 57, and
n day 28 of the post-treatment period; for subjects in Cohort A
f each group, further samples were collected on days 8 and 22.
nti-HBsAg antibodies were measured by electrochemilumines-
ence assays (anti-HBS kits, Roche) and anti-HBcAg antibodies by
ualitative chemiluminescent immunoassays (ADVIA Centaur HBc
otal kits [Siemens Healthcare Diagnostics, Malvern, PA]).subject ﬂow through the study.
2.11. Human leukocyte antigen typing
HLA typing was  performed by DNA sequence-based methodol-
ogy (Abbott Molecular, Abbott Park, IL) using buccal swabs obtained
from subjects prior to dosing on day 1. The following exons were
routinely sequenced: HLA-A, B, C: Exons 2, 3, 4; HLA-DRB1: Exon
2; HLA-DQB1: Exons 2, 3. Remaining ambiguities were resolved
by application of “heterozygosity ambiguity resolution primers”
(Abbott) or by PCR-SSP (Life Technologies, Carlsbad, CA).
2.12. Statistical analysis
No formal analysis was performed to determine sample size or
to assess safety data. The IFN- ELISpot and LPA algorithms and
response criteria together with ASCA response criteria were pre-
deﬁned. All randomized subjects who received at least one dose of
study treatment were included in the safety analysis.
3. Results
3.1. Subjects
Sixty subjects were randomized of whom 57 completed the
study (Fig. 1). Three subjects were discontinued because of an
adverse event (n = 1) and protocol violation (n = 2). Demographic
and baseline subject characteristics were similar for Cohorts A and
B (Table 1).
3.2. Safety and tolerabilityThirty-nine (65%) subjects reported adverse events (Table 2); all
were graded mild or moderate and none was  serious. A full listing
of moderate adverse events is shown in Supplementary Table 5.
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Table 1
Demographic and baseline subject characteristics.
GS-4774 dose
10 YU 40 YU 80 YU
Cohort A
(Weekly)
N = 10
Cohort B
(Monthly)
N = 10
Cohort A
(Weekly)
N = 10
Cohort B
(Monthly)
N = 10
Cohort A
(Weekly)
N = 10
Cohort B
(Monthly)
N = 10
Age in years, mean [range] 48.8 [31–69] 42.9 [27–65] 37.7 [30–50] 33.2 [22–54] 38.9 [28–57] 39.3 [22–50]
Male,  n (%) 2 (20) 4 (40) 4 (40) 7 (70) 5 (50) 3 (30)
Weight in lbs, mean (SD) 172.6 (40.94) 164.9 (26.15) 181.2 (41.70) 165.6 (29.76) 178.9 (56.35) 170.2 (43.22)
Race,  n (%)
White 9 (90) 10 (100) 10 (100) 10 (100) 8 (80) 9 (90)
Black  1 (10) 0 0 0 0 1 (10)
Native American 0 0 0 0 2 (20) 0
Ethnicity, n (%)
Hispanic/Latino 5 (50) 6 (60) 8 (80) 8 (80) 7 (70) 8 (80)
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D, standard deviation.
ne subject who received monthly injections of 80 YU GS-4774
as discontinued due to mild paresthesia, which resolved and was
udged by the Investigator to be related to study treatment. The
umber of individual adverse events increased with dose and more
dverse events were reported following weekly than monthly dos-
ng. Most adverse events reported were judged related to study
reatment by the Investigator; all of these were injection-site reac-
ions except for one transient episode of headache in the 40 YU
roup and another of myalgia in the 80 YU dose group. Adverse
vents experienced by more than one subject in a single cohort are
hown in Supplementary Table 6.
The most frequent adverse events were injection-site reactions,
eported by 23 (38%) subjects (Table 2). Injection-site reactions
ere reported more frequently after weekly (n = 15 subjects) than
onthly dosing (n = 8). All reactions resolved and were mild with
he exception of two episodes of moderate injection-site pain
eported by one subject in Cohort A 80 YU. Both episodes resolved
ithout treatment and were judged to be related to study treat-
ent. Two of the mild injection-site reactions (induration and pain)
equired treatment (acetaminophen and ice).
Four patients had Grade 3 decreases in hemoglobin (two in
ohort A 10 YU, one in Cohort B 40 YU, and one in Cohort B 80 YU).
here were no other Grade ≥2 laboratory abnormalities. Only
wo laboratory abnormalities were reported as adverse events:
ecrease in absolute neutrophils and white blood cell counts
y one subject in Cohort A 40 YU. Both events were mild and
able 2
dverse events including injection-site reactions reported by the subjects in each cohort.
GS-4774 dose
10 YU 
Cohort A
(Weekly)
N = 10
Cohort B
(Monthly)
N = 10
Patients with ≥1 AE, n (%) 7 (70) 4 (40) 
Mild  5 (50) 4 (40) 
Moderate 2 (20) 0 
Patients with ≥1 SAE, n (%) 0 0 
Number of AEs 19 10 
Mild,  n (% total) 17 (89) 10 (100) 
Moderate, n (% total) 2 (11) 0 
Severe, n (% total) 0 0 
Injection-site reactions
Subjects with reactions, n (% total) 1 (1) 1 (10) 
Injection-site reactions, n (% total AEs) 4 (21) 1 (10) 
Mild,  n (% reactions) 4 (100) 1 (100) 
Moderate, n (% reactions) 0 0 
E, adverse event; SAE, serious adverse event. (20) 2 (20) 3 (30) 2 (20)
considered not related to study treatment. No clinically relevant
changes were reported for vital signs or ECG.
3.3. Immunogenicity
Fifty-two (88%) subjects showed an immune response by at least
one measure of T-cell immune function (Table 3).
3.4. IFN- ELISpot assay
The highest frequency of IFN- ELISpot responders occurred in
the highest dose group: 9/20 (45%) subjects in the 10 YU group,
7/20 (35%) subjects in the 40 YU group, and 14/19 (74%) sub-
jects in the 80 YU group (Table 3). The frequency of responders
was similar between immunization cohorts across all dose groups,
including the two highest dose groups. A total of 14/29 (48%)
subjects responded in Cohort A (weekly dosing) and 16/30 (53%)
subjects in Cohort B (monthly) (Table 3). At the lowest dose, how-
ever, the monthly immunization regimen generated a 2-fold higher
frequency of ELISpot responders than the weekly regimen.
The kinetics of the emergence of the IFN- ELISpot response was
dependent on dose and immunization regimen. While responses
were seen as early as day 15, generally the highest responses
occurred at later time-points (Fig. 2). For 80 YU, 7/14 (50%) of even-
tual responders exhibited IFN- responses by day 15 whereas for
10 and 40 YU there was a slower kinetics with only 1/9 (11%) and
40 YU 80 YU
Cohort A
(Weekly)
N = 10
Cohort B
(Monthly)
N = 10
Cohort A
(Weekly)
N = 10
Cohort B
(Monthly)
N = 10
9 (90) 6 (60) 7 (70) 6 (60)
8 (80) 5 (50) 6 (60) 5 (50)
1 (10) 1 (10) 1 (10) 1 (10)
0 0 0 0
70 19 101 93
69 (99) 18 (95) 99 (98) 91 (98)
1 (1) 1 (5) 2 (2) 2 (2)
0 0 0 0
8 (80) 2 (20) 6 (60) 5 (50)
51 (73) 3 (16) 76 (77) 67 (74)
51 (100) 3 (100) 74 (97) 67 (100)
0 0 2 (3) 0
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Table  3
Immunogenicity summary.
GS-4774 dose
10 YU 40 YU 80 YU
Cohort A
(Weekly)
N = 10
Cohort B
(Monthly)
N = 10
Cohort A
(Weekly)
N = 10
Cohort B
(Monthly)
N = 10
Cohort A
(Weekly)
N = 10
Cohort B
(Monthly)
N = 10
ELISpot, n/N (%) 3/10 (30.0) 6/10 (60.0) 4/10 (40.0) 3/10 (30.0) 7/9 (77.8)a 7/10 (70.0)
LPA,  n/N (%)b 6/8 (75.0) 4/5 (80.0) 9/9 (100.0) 9/9 (100.0) 9/9 (100.0)a 8/10 (80.0)
Total  immune responders, n/N (%)c 8/10 (80.0) 7/10 (70.0) 10/10 (100.0) 9/10 (90.0) 9/9 (100.0) 9/10 (90.0)
n, number of responders; N, number of subjects analyzed.
exclud
for LPA
1
a
a
g
(
F
E
j
ba One subject terminated early and only received Day 1 dosing. This subject was 
b Some subjects had insufﬁcient recovery of peripheral blood mononuclear cells 
c Response in either ELISpot or LPA or both assays.
/7 (14%), respectively, eventual responders exhibiting responses
t this early timepoint. On day 15, there were also almost twice
s many responders in Cohort B than in Cohort A across dose
roups: 3/14 (21%) eventual responders in Cohort A versus 6/16
38%) in Cohort B. The majority of ELISpot responders (18/30 [60%])
ig. 2. Combined responses to HBsAg, HBcAg, and HBx as determined by IFN-
LISpot after weekly (circles) and monthly (squares) immunization of healthy sub-
ects with 10 YU (A), 40 YU (B) and 80 YU (C) GS-4774. Responses are shown after
ackground and baseline adjustment as described in the text.ed from ELISpot and LPA analysis.
 analysis.
demonstrated responsiveness by the end of the study, 28 days fol-
lowing the ﬁnal immunization.
In the 10 YU group, ELISpot responses were preferentially seen
when PBMCs were stimulated with HBV recombinant antigens. In
contrast, in the 40 and 80 YU groups, there was  a 2-fold higher
frequency of ELISpot responders to peptide pools. The production
of IFN- in response to stimulation with HBV recombinant anti-
gens was  mainly directed to HBsAg and HBcAg (43% to HBsAg or
HBcAg versus 20% to HBx). Across dose groups, the majority of
ELISpot responses after stimulation of PBMCs with peptide pools
were directed to overlapping pools of 15-residue peptides repre-
senting the HBV insert sequence.
3.5. Lymphocyte proliferation assay
Lymphocyte proliferation in response to HBV recombinant anti-
gens was  observed in most (90%) subjects. The number of LPA
responders was  slightly higher in the two  highest dose groups (40
and 80 YU: 100% and 90%, respectively) compared with the lowest
dose group (10 YU: 77%) (Table 3). The frequency and magnitude of
LPA responses were similar regardless of the immunization reg-
imen (Cohort A: 92%; Cohort B: 88%) (Fig. 3). In contrast to the
ELISpot results, approximately 50% of subjects across dose groups
displayed responses by day 15 (Fig. 3). However, the number of
LPA responders was lowest at this time-point compared with later
times.
All three HBV antigens were able to stimulate lymphocyte pro-
liferation; HBcAg elicited the highest number of LPA responders
across dose groups and HBx the lowest. The breadth of the response
(deﬁned as those displaying LPA responses to all three antigens)
was similar for the 10 and 40 YU groups (50% and 56%, respectively)
and higher than for the 80 YU group (29%). The magnitude of prolif-
eration was  similar across groups: 25 subjects had an SI > 5 and 12
subjects had an SI > 10 at any time-point compared with baseline.
Proliferative responses of greatest magnitude (SI > 10) across dose
groups were elicited by HBcAg.
3.6. Anti-S. cerevisiae antibody
The frequency of ASCA responders was  low, although there were
more responders in Cohort A (seven subjects, 12%) than Cohort B
(one subject, 2%). There was also a slight trend toward higher IgA
and IgG levels in Cohort A. The total number of responders (IgA plus
IgG) was the highest in Cohort A 80 YU (ﬁve subjects, 8%). Gener-
ally, IgA and IgG levels were low at baseline with only six subjects
showing a baseline response ≥25 U. These low levels were main-
tained during treatment. Seven of the eight ASCA responders were
also deﬁned as responders in the ELISpot. In addition, for 80 YU, all
ASCA responders also displayed ELISpot and LPA responses.
4930 A. Gaggar et al. / Vaccine 32
Fig. 3. Combined responses to HBsAg, HBcAg, and HBx as determined by LPA after
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oeekly (circles) and monthly (squares) immunization of healthy subjects with 10 YU
A),  40 YU (B) and 80 YU (C) GS-4774. Dotted line: SI = 2, denotes threshold for
esponse. SI was  adjusted for background and baseline as described in the text.
.7. Anti-HBcAg and anti-HBsAg
No anti-HBcAg antibodies were detected at any time during the
tudy and no anti-HBsAg antibody levels >8.4 IU/mL were deter-
ined. Two subjects, both in Cohort A 80 YU, had anti-HBsAg levels
3.5 IU/L during the study.
.8. HLA
HLA testing was performed to evaluate for any HLA restriction
f immune responses to GS-4774. The most frequent HLA alleles
ere A*02, C*07, DQB1*03, and DRB1*04. No association was  found
etween common HLA alleles and the IFN- ELISpot response to
eptides or recombinant antigens (Supplementary Table 7).
. DiscussionIn the present study, GS-4774 was generally safe and well-
olerated. The most common adverse events were injection-site
eactions. Adverse events occurred more frequently in both cohorts
f the highest dose group, 80 YU, and the number of individual (2014) 4925–4931
adverse events was higher after weekly than monthly immu-
nization. Immunization with GS-4774 led to HBV antigen-speciﬁc
and treatment-emergent T-cell responses. The majority of sub-
jects showed a response when assessed by at least one of the
assays. GS-4774 was  immunogenic at all three doses tested and
both immunization regimens, weekly and monthly dosing, induced
T-cell-mediated immune responses. Immunogenicity was inde-
pendent of HLA alleles.
LPA responses were observed in the majority of subjects with
no increase in the frequency of responders related to dose or
timing of dose. LPA responses were measured using recombinant
HBV proteins which preferentially utilize an MHC  Class II pathway
resulting in a bias toward CD4+ T-cell activation [12]. The responses,
therefore, may  represent early CD4+ T-cell activation with GS-
4774 in these subjects. The higher magnitude LPA responses with
SI > 5, breadth of proliferative responses to recombinant antigens,
and timing of response emergence suggested an increase in LPA
responses from 10 to 40 YU doses but not from 40 to 80 YU.
IFN- ELISpot responses were seen in fewer subjects and at
later time-points than LPA responses. This assay did not differ-
entiate CD4+ from CD8+ T-cell responses, although as performed
the assay biases toward CD4+ T-cell responses. Because there were
more ELISpot responses at later time-points, further protracting
treatment may  augment the CD8+ T-cell response. IFN- ELISpot
responses were comparable between all weekly and monthly regi-
mens. Also, responses were similar in the monthly 10 and 80 YU
dose groups, suggesting a dose-independent response on monthly
regimens. The slightly lower ELISpot response rate in the 40 YU
compared with 10 or 80 YU dose groups is puzzling but may  be
an artifact of sample variability or inter-subject differences. Our
results show promise that immunization with GS-4774 may  suc-
cessfully clear viral loads in patients with chronic HBV infection,
although the inﬂuence of altered immune function in these individ-
uals on vaccine activity remains unknown in the absence of clinical
trials.
Injection-site reactions after administration of an HBV vaccine
are commonly reported in studies conducted in healthy subjects
[13–15]. Based on its mechanism of action, GS-4774 is likely to
interact with antigen-presenting cells in the subcutaneous layer
of the skin and elicit a local immune response. Furthermore, the
highest dose group required four injections per dose and this likely
contributed to the increased number of injection site reactions in
this group. Therefore, the injection-site reactions (i.e. local immune
responses) observed in the present study were not unexpected and
are similar to those seen in prior studies evaluating the yeast plat-
form for vaccination [16–18].
Our safety and immunogenicity data provide the rationale
for the selection of dose and immunization regimens in future
studies with GS-4774. The safety analysis revealed a clear dose-
dependent increase in the frequency of adverse events. Compared
with monthly immunization, weekly immunization was associated
with a higher incidence of adverse events, including injection-site
reactions, and with increased ASCA responses. The impact of ASCA
responses on the anti-HBV immune response to GS-4774 is not
known and should be evaluated in longer dosing regimens with
GS-4774. The LPA data indicated no apparent beneﬁt in increasing
the GS-4774 dose from 40 to 80 YU.
Prior attempts at therapeutic vaccines for chronic infection with
HBV have mainly used recombinant proteins or peptides coupled
with an adjuvant to induce a B-cell response and have largely been
unsuccessful [19–21]. GS-4774 was  developed to include more por-
tions of the HBV genome than prior vaccine candidates and is
developed with a platform that allows MHC  Class I and Class II
display of processed peptides. The ability to induce or augment
the CD4+ and CD8+ T-cell responses to HBV may  allow for stable
control of HBV DNA within hepatocytes, resulting in no detectable
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iscontinued. Conﬁrmation of these concepts in patients with CHB
ill require further evaluation of GS-4774 in clinical trials.
In conclusion, GS-4774 was safe and well-tolerated in healthy
ubjects with injection-site reactions being the most frequently
eported adverse events. GS-4774 was immunogenic and both
eekly and monthly regimens led to rigorous immune responses
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